SCHEMBL2790948

SCHEMBL2790948

CC(C)c1oc(-c2ccccc2)nc1C(=O)OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TARBP2 Q15633 2/20 0.53
ALDH1A1 P00352 9/20 0.51
SMN1; SMN2 Q16637 6/20 0.51
NPC1 O15118 5/20 0.51
RAB9A P51151 5/20 0.51
HPGD P15428 5/20 0.51
KDM4E B2RXH2 4/20 0.51
HSD17B10 Q99714 3/20 0.51
KMT2A Q03164 2/20 0.51
PPARG P37231 1/20 0.48
PPARA Q07869 1/20 0.48
TSHR P16473 2/20 0.48
POLB P06746 1/20 0.47
ATM Q13315 1/20 0.47
MAPT P10636 2/20 0.47
ALOX15 P16050 1/20 0.47
TACR1 P25103 1/20 0.46
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14504405 0.84 KDM4E (0.63) TARBP2ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL2490988 0.82 TARBP2 (0.59) TARBP2ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL22343083 0.81 ATM (0.46) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL2792875 0.81 IKBKB (0.50) TARBP2ALDH1A1NPC1RAB9AHPGD
SCHEMBL1051765 0.78 TARBP2 (0.71) TARBP2ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL26861088 0.75 TDP1 (0.47) ALDH1A1RAB9AHPGDKDM4EKMT2A
SCHEMBL28161840 0.75 ALDH1A1 (0.54) TARBP2ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL3616364 0.74 TARBP2 (0.62) TARBP2ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL14663603 0.73 MMEL1 (0.46) TACR1
SCHEMBL13685244 0.71 KDM4E (0.41) TARBP2ALDH1A1NPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963313-B1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) MADRIGAL PHARMACEUTICALS INC (US) 2012-11-14 EP disclosed
US-20100190979-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. 2010-07-29 US disclosed
US-20100168419-A1 Diacylglycerol Acyltransferase Inhibitors BOLIN DAVID ROBERT 2010-07-01 US disclosed
US-7714126-B2 Diacylglycerol acyltransferase inhibitors VIA PHARMACEUTICALS, INC. (US) 2010-05-11 US disclosed
CN-101316844-A Inhibitors of diacylglycerol acyltransferase (DGAT) HOFFMANN LA ROCHE (CH) 2008-12-03 CN disclosed
EP-1963313-A2 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) F.HOFFMANN-LA ROCHE AG (CH) 2008-09-03 EP disclosed
WO-2007060140-A2 INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE (DGAT) F. HOFFMANN-LA ROCHE AG (CH) 2007-05-31 WO disclosed
US-20070123504-A1 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168419-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT TARBP2 2863/4885ALDH1A1 573/4885SMN1; SMN2 4066/4885
US-20100190979-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT2, DGAT1, LCAT TARBP2 2863/4885ALDH1A1 573/4885SMN1; SMN2 4066/4885
US-20070123504-A1 Diacylglycerol acyltransferase inhibitors DGAT2, DGAT1, LCAT TARBP2 2863/4885ALDH1A1 573/4885SMN1; SMN2 4066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.